The New England Journal of Medicine,
Survival longer with cemiplimab than with single-agent chemotherapy among patients with recurrent cervical cancer after first-lin…
Survival with Cemiplimab in Recurrent Cervical Cancer
Overview of attention for article published in New England Journal of Medicine, February 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Mentioned by
- news
- 98 news outlets
- blogs
- 2 blogs
- 50 X users
- 1 Facebook page
- guideline
- 9 clinical guideline sources
- podcasts
- 2 podcasts
Readers on
- mendeley
- 265 Mendeley